Sussex Research Acquires Chemaphor Chemical Services from Avivagen
Ottawa, Canada October 13, 2017 – Sussex Research Laboratories Inc. (Sussex Research), the leading specialist in the synthesis of carbohydrate and stable isotope-labeled molecules, is pleased to announce the successful acquisition of Chemaphor Chemical Services (“Chemaphor”) and its product portfolio from Avivagen Inc. The acquisition strengthens the company’s capabilities and product offering of high-purity stable isotope-labeled products, particularly Vitamin D and E, for use in biological research, drug discovery, medical diagnostic, food and dairy testing and other laboratory applications.
Dr. Brady Clark, Founder & CEO of Sussex Research comments: “Chemaphor has been providing very high purity stable isotope-labeled products and custom synthesis services relating to vitamins for nearly two decades. The acquisition of Chemaphor, its products and its chemists is an important step in further enhancing the global leadership of Sussex Research in the demanding fields of carbohydrate and stable isotope-labeling of bioorganic molecules and small molecule API. This strengthens our position in international R&D markets and also provides immediate access to additional production capacity for our growing product/project portfolios.”
Dr. Graham Burton, cofounder and Chief Scientific Officer at Avivagen Inc., continues: “Keith Ingold and I pioneered use of stable isotope-labeled vitamin E in research dating back several decades. Chemaphor has been an important part of Avivagen’s growth. Nevertheless, Avivagen is now fully committed to commercializing our animal health supplement products. I’m very pleased that Sussex Research can provide its full attention to these high quality labelled products. This is a great opportunity for the former Chemaphor staff to join the international leader in carbohydrate synthesis and stable isotope-labeling, where there will be ample opportunity to expand the product portfolio, expand contract research and development while also gaining access to a wider marketing effort.”
About Avivagen
Avivagen is developing and commercializing products for livestock feeds to replace antibiotics for growth promotion and to help prevent disease by supporting the animal’s own health defences. The Corporation’s unique, proprietary technology is known as OxC-beta™ (fully-oxidized beta-carotene) technology.
About Sussex Research
Sussex Research is a contract research organization and leading specialist in the design, synthesis and characterization of carbohydrate-based systems and stable isotope-labeled molecules. We excel at synthesis of molecules that incorporate elements of carbohydrates, glycans and polysaccharides. Our product portfolio and contract synthesis services enable our clients and partners to explore and exploit glycosylation or stable isotope-labeling for drug discovery, drug delivery, carbohydrate-based vaccine development, therapeutic enhancement and bio-analytical assay development.
Contact:
For further questions, please visit our websites or contact the person below.
Sussex Research Laboratories Inc.
Brady Clark, Ph.D., CEO
Tel.: 1 613 993 4402
Fax: 1 613 949 5993
info@sussex-research.com
www.sussex-research.com
Avivagen Inc.
Munawara Dar, Administrator
Tel: 1 613 949 8164
Fax: 1 613 993 0796
m.dar@avivagen.com
www.avivagen.com
Sussex Research Receives Notice of Allowance for Glycopeptide Cosmetic Active Technology Patent
OTTAWA, Canada, September 21, 2017 – Sussex Research Laboratories Inc. (“Sussex Research”), the leading specialist in carbohydrate synthesis, glycosylation and glycodesign, is pleased to announce that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application No. 15/103,452 entitled “GLYCOPEPTIDE COMPOSITIONS AND USES THEREOF.” The patent covers the Company’s novel cosmetic active ingredient, GlycolastinTM, a glycosylated peptide developed as an anti-wrinkling cosmetic active that efficiently improves the appearance of fine lines and wrinkles while also increasing skin hydration and elasticity. In vitro studies have shown that GlycolastinTM stimulates at least 3 major constituents of skin that are all important for the maintenance of healthy skin. In vivo studies demonstrated that, within 42 days, crow’s feet wrinkles were visibly decreased while also improving skin hydration and elasticity.
Dr. Brady Clark, President and Chief Executive Officer stated: “This is the first of what we hope will be several patents that we expect to receive to protect our GlycolastinTM technology which utilizes glycosylation to improve the effectiveness of cosmetic peptide actives. We expect finished products that utilize this unique active to be introduced in 2018.”
About Glycolastin™
Glycolastin™has been developed by Sussex Research to exploit the field of glycobiology in order to advance a new and state-of-the-art anti-aging technology. In vitro studies have shown that Glycolastin™ is significantly more efficient at stimulating structural protein synthesis in skin cells than the non-glycosylated peptide active, a well-known peptide active in the cosmetics field. Increased secretion of structural proteins elastin, fibronectin and collagens by fibroblasts was observed in vitro for glycosylated peptides compared to the non-glycosylated reference peptide. The in vitro effect on elastin secretion has also been confirmed independently in a 3D ex vivo skin model. Patents have been filled in numerous jurisdictions.
About Sussex Research:
Sussex Research is a contract research organization and leading specialist in the design, synthesis and characterization of carbohydrate-based systems and stable isotope-labeled molecules. We excel at synthesis of molecules that incorporate elements of carbohydrates, glycans and polysaccharides. Our product portfolio and contract synthesis services enable our clients and partners to explore and exploit glycosylation or stable isotope-labeling for drug discovery, drug delivery, carbohydrate-based vaccine development, therapeutic enhancement and bio-analytical assay development. For more information visit www.sussex-research.com.
Sussex Research Announces Successful Clinical Trial Results for Glycolastin(TM) its novel anti-aging glycopeptide cosmetic active.
OTTAWA, Canada, August 17, 2015 – Sussex Research Laboratories Inc. (“Sussex Research”), the leading specialist in carbohydrate synthesis, glycosylation and glycodesign, is pleased to announce that its clinical trial for GlycolastinTM, an anti-aging glycopeptide cosmetic active, has successfully concluded. The in vivo study involved 26 healthy female volunteers between 37-67 years of age. The study was a monocentric open-label trial carried out by Evalulab Inc. of Montreal, Canada.
Dermal irritation patch (48hrs) and HRIPT tests revealed that the active may be considered a non-irritant and hypo-allergenic. The formulated Glycolastin™ test product was also very well tolerated over the 42D study period. According to the results reported in this study, Glycolastin™ may be considered as an effective and novel anti-aging ingredient demonstrating significant improvement in skin firmness, hydration and profilometry results (reduction of fine lines, moderate and deep wrinkles). A few results are summarized below:
Fine Lines (Class 1) – significant reduction of 24% (p<0.01) in the number of wrinkles at 42 days with maximal reduction up to 74%
Medium Wrinkles (Class 2) – significant reduction of 16% (p<0.01) at 42 days with effectiveness up to 76%
Deep Wrinkles (Class 3) – significant decrease by 27% (p<0.01) at 42 days with maximal observed improvement of 86%
Dr. Brady Clark, Founder & CEO of Sussex Research comments: “We are very excited that our scientific studies translated to this excellent result in the clinic. It was the dramatic observations made during in vitro and ex vivo studies that prompted us to patent the glycopeptide technology and undertake the clinical trial. As a company that has worked with numerous partners on glycosylation of peptides and other biological molecules, we have known for many years that glycosylation can markedly improve the effectiveness of peptides and other biological molecules. It’s very gratifying to show that glycosylation can be very useful for cosmetic actives as well.”
Plans are underway to commercialize GlycolastinTM as a cosmetic active in topical anti-aging products.
About Glycolastin™
Glycolastin™has been developed by Sussex Research to exploit the field of glycobiology in order to advance a new and state-of-the-art anti-aging technology. In vitro studies have shown that Glycolastin™ is significantly more efficient at stimulating structural protein synthesis in skin cells than the non-glycosylated peptide active, a well-known peptide active in the cosmetics field. Increased secretion of structural proteins elastin, fibronectin and collagens by fibroblasts was observed in vitro for glycosylated peptides compared to the non-glycosylated reference peptide. The in vitro effect on elastin secretion has also been confirmed independently in a 3D ex vivo skin model. Patents have been filled in numerous jurisdictions.
About Sussex Research:
As a leading specialist in glycodesign and the synthesis of complex carbohydrates, Sussex Research excels at the discovery and development of molecules that explore and exploit glycobiology. Sussex Research excels in the design, synthesis and characterization of molecules that incorporate glycotechnology. Our unique product portfolio and carbohydrate synthesis capabilities enable researchers across a variety of scientific disciplines to readily explore and exploit glycobiology in order to enhance the therapeutic potential of small molecules, peptides, proteins, lipids and oligonucleotides. For more information visit www.sussex-research.com.
Sussex Research Presents Data on “Post Translationally Modified Cosmeceutical Actives” at the International Federation of Societies for Cosmetic Chemists (IFSCC) Congress in Paris.
Paris, France, October 28, 2014 – Sussex Research scientists presented data on the Company’s promising research & development program on carbohydrate-based anti-aging actives. Sussex Research scientists presented the latest results on the Company’s anti-aging carbohydrate-based molecules at the International Federation of Societies for Cosmetic Chemists Congress in Paris, France. The poster, entitled “Post Translationally Modified Cosmeceutical Actives,” was extremely well received.
About Sussex Research: As a leading specialist in glycodesign and the synthesis of complex carbohydrates, Sussex Research excels at the discovery and development of molecules that explore and exploit glycobiology. Sussex Research excels in the design, synthesis and characterization of molecules that incorporate glycotechnology. Our unique product portfolio and carbohydrate synthesis capabilities enable researchers across a variety of scientific disciplines to readily explore and exploit glycobiology in order to enhance the therapeutic potential of small molecules, peptides, proteins, lipids and oligonucleotides. For more information visit www.sussex-research.com.
Sussex Research Collaborator Receives Grant to Develop Glycan-Labelled BODIPY Fluorophores For Use In Glycobiology
Ottawa, Canada, September 5, 2014 – Sussex Research Laboratories Inc. announced today that Professor Hongbin (Tony) Yan of Brock University has received an NSERC Engage grant for a project entitled Labelling glycans with BODIPY fluorophores.
BODIPY fluorophores possess a number of unique properties that have led to their increasing popularity in a wide range of applications. Compared with other commercially available fluorophores such as fluoresceins, rhodamines, and cyanines, BODIPY fluorophores are in general more stable, both chemically and photochemically. Moreover, BODIPY fluorescent properties are relatively pH- and environment-independent, which is a very useful feature in many applications.
The project is expected to combine Sussex Research expertise in the preparation of glycoconjugates and glycans having functionalized linker/spacer systems with the Brock team’s capabilities in BODIPY chemistry. The project is expected to result in a new class of BODIPY fluorophore functionalized carbohydrate-based products.for use in the fields of molecular biology and glycobiology.
According to Brady Clark, President & CEO of Sussex Research, “As industrial partner on the project, Sussex Research is very pleased to support Professor Yan and his research team. The Yan laboratory are experts in BODIPY chemistry with a proven track record of working with BODIPY. This collaboration will extend the novel product portfolio of Sussex Research and make BODIPY-labelled glycans available to researchers worldwide.”
About Sussex Research: As a leading specialist in glycodesign and the synthesis of complex carbohydrates, Sussex Research excels at the discovery and development of molecules that explore and exploit glycobiology. Sussex Research excels in the design, synthesis and characterization of molecules that incorporate glycotechnology. Our unique product portfolio and carbohydrate synthesis capabilities enable researchers across a variety of scientific disciplines to readily explore and exploit glycobiology in order to enhance the therapeutic potential of small molecules, peptides, proteins, lipids and oligonucleotides. For more information visit www.sussex-research.com.
Pharmaceutical Technology Interviews Sussex Research CEO, Dr. Brady Clark, on the “Role of NMR and Mass Spectroscopy in Glycan Analysis.”
Ottawa, Canada, January 2, 2014 – Pharmaceutical Technology recently interviewed Sussex Research scientists, including Dr. Brady Clark, on the role of Nuclear Magnetic Resonance Spectroscopy (NMR) and Mass Spectrometry (MS) in Glycan Synthesis and Analysis. Sussex Research is a well known specialist in carbohydrate synthesis and glycodesign with an established international reputation. As discussed in the interview, NMR and MS are vital to successful development of glycosylation in syntheses of carbohydrate-based molecules and glycans. While NMR analysis provides crucial structural information of synthesized glycans that cannot be determined in any other way, MS analysis confirms molecular weight of target synthons. In bioanalytical analyses, LC-MS/MS is ideal for quantitation of free sugars in biological matrices.
To read the full article, you are directed to PharmaTech.com (http://www.pharmtech.com/role-nmr-and-mass-spectroscopy-glycan-analysis).
About Sussex Research: As a leading specialist in glycodesign and the synthesis of complex carbohydrates, Sussex Research excels at the discovery and development of molecules that explore and exploit glycobiology. Sussex Research excels in the design, synthesis and characterization of molecules that incorporate glycotechnology. Our unique product portfolio and carbohydrate synthesis capabilities enable researchers across a variety of scientific disciplines to readily explore and exploit glycobiology in order to enhance the therapeutic potential of small molecules, peptides, proteins, lipids and oligonucleotides. For more information visit www.sussex-research.com.
Sussex Research Presents Data on “Post Translationally Modified Cosmeceutical Actives” at the Society for Cosmetic Chemists in New York.
New York, December 12, 2013 – Sussex Research scientists gave the first glimpse into the Company’s promising research & development program on carbohydrate-based anti-aging actives. Sussex Research scientists presented the latest results on the Company’s anti-aging carbohydrate-based molecules at the annual Society for Cosmetic Chemists in New York. The poster, entitled “Post Translationally Modified Cosmeceutical Actives,” was extremely well received.
About Sussex Research: As a leading specialist in glycodesign and the synthesis of complex carbohydrates, Sussex Research excels at the discovery and development of molecules that explore and exploit glycobiology. Sussex Research excels in the design, synthesis and characterization of molecules that incorporate glycotechnology. Our unique product portfolio and carbohydrate synthesis capabilities enable researchers across a variety of scientific disciplines to readily explore and exploit glycobiology in order to enhance the therapeutic potential of small molecules, peptides, proteins, lipids and oligonucleotides. For more information visit www.sussex-research.com.
SUSSEX RESEARCH COLLABORATOR RECEIVES NSERC GRANT TO IMPROVE THE MANUFACTURE OF PSEUDAMINIC ACID
Ottawa, Canada, January 17, 2012 – Sussex Research Laboratories Inc. announced today that Professor Christopher N. Boddy of the University of Ottawa has received an NSERC Engage grant for a project entitled Development of a process for the manufacture of pseudaminic acid.
Pseudaminic acid, a sialic acid (neuraminic acid) analogue, represents a promising new class of bacterial sugars with relevance in medicine and biology. Pseudaminic acid containing glycoconjugates are thought to influence pathogenesis through bacterial adhesion, invasion, and immune evasion, and are associated with bacterial cell surface structures such as lipopolysaccharide, capsular polysaccharide, pili and flagella. However, there is no cost-effective method available for the production of this rare sugar.
According to Brady Clark, President & CEO of Sussex Research, “As industrial partner on the project, Sussex Research is very pleased to support Professor Boddy and his research team. The Boddy laboratory are experts in metabolic engineering and have a track record of developing manufacturing processes at the research level, including the development of a commercial fermentation-based process for the production of sialic acid. This collaboration will extend the ability of Sussex Research to make pseudaminic acid available in larger quantities and at reasonable cost to researchers worldwide.”
Development of a fermentation-based process for the manufacture of pseudaminic acid requires metabolic engineering to optimize the production strain and development of an efficient low cost isolation procedure. The Boddy group has been and will continue to work in collaboration with Ian Schoenhofen of the National Research Council (NRC) of Canada, who previously developed the in vitro enzymatic methodology for pseudaminic acid production at milligram scales.
About Sussex Research: Sussex Research is a well known specialist in carbohydrate synthesis and associated methodology development. As a carbohydrate-enabling company with an established international reputation, Sussex Research excels in the design, synthesis and characterization of carbohydrate-based molecules. The company’s unique product portfolio and custom synthesis service enables researchers across a wide variety of scientific research disciplines to readily explore and exploit carbohydrates and carbohydrate modified molecules such as glycoamino acids, glycopeptides, oligosaccharides, special carbohydrate linker/spacer systems and other glycoconjugates in numerous and diverse applications. For more information visit www.sussex-research.com.
SUSSEX RESEARCH LABORATORIES APPOINTS WAKO CHEMICAL INDUSTRIES AS A DISTRIBUTOR FOR ITS CARBOHYDRATE-BASED PRODUCTS & SERVICES IN JAPAN
Ottawa, Canada, May 25, 2010 – Sussex Research Laboratories Inc. has appointed Wako Pure Chemical Industries (Osaka, Japan) as a non-exclusive distributor of Sussex’s complete line of carbohydrate-based reagents (glycoreagents) in Japan. Sussex Research develops and manufactures sophisticated carbohydrate-based molecules for advanced academic research as well as for research & development in the pharmaceutical and biotechnology industries.
Under the new distribution agreement, Sussex glycoreagents are to be marketed under the Sussex Research label and sold, in research quantities, via Wako’s catalogue, sub-distributors and dealer network throughout Japan.
According to Brady Clark, Ph.D., President of Sussex Research, “We are very pleased to be working with Wako, which is renowned for its high purity chemical reagents. We perceive Wako as the leader in Japan for the provision of premium quality research reagents. Scientists in Japan are highly recognized for contributions in glycoscience. This collaboration will extend our ability to make these important glycoreagents including glycoamino acids, glycopeptides, oligosaccharides, PEGylated Glycosides and other unique carbohydrate-based molecules and glycoconjugates available to researchers in Japan.”
About Sussex Research: Sussex Research is a well known specialist in carbohydrate synthesis with an established international reputation. As a carbohydrate-enabling company, Sussex Research excels in the design, synthesis and characterization of carbohydrate-based molecules. The company’s unique product portfolio and custom synthesis service enables researchers across a variety of scientific disciplines to readily explore and exploit carbohydrates and carbohydrate modified molecules such as glycoamino acids, glycopeptides, oligosaccharides, special carbohydrate linker/spacer systems and other glycoconjugates in numerous and diverse applications.
Sussex Research Introduces Unique Sialic Acid-like Pseudaminic Acid Products for Research into Infectious Diseases
Ottawa, Canada, June 25, 2007 – Sussex Research, a leader in advanced glycosylation chemistry and carbohydrate synthesis, today announced that it now manufactures the rare bacterial saccharide, Pseudaminic Acid, along with its nucleotide activated form, CMP-Pseudaminic Acid. These unique saccharides are currently available commercially to researchers worldwide.
Pseudaminic Acid (Pse) (5,7-diacetamido-3,5,7,9-tetradeoxy-L-glycero- -L-manno-nonulosonic acid) is a sialic acid-like, nine-carbon saccharide that was first identified in the lipopolysaccharides (LPS) of Pseudomonas aeruginosa in 1984. The sugar modification has since been observed in several other organisms including the gastrointestinal pathogens Helicobacter pylori and Campylobacter jejuni. The Pse saccharides are thought to influence pathogenesis through bacterial adhesion, invasion, and immune evasion. Pseudaminic Acid has been found in Gram-negative bacterial cell-surface glycoconjugates, such as LPS, capsular polysaccharide, pili and flagella, all of which are important for pathogenesis.
Pseudaminic Acid is unique to bacteria. Many of the bacteria with which Pse has been identified, such as H. Pylori, are associated with serious gastrointestinal diseases that afflict millions of people worldwide. Because of this, its biosynthetic pathway offers potential as a novel therapeutic target and for future small molecule inhibitor screening and design.
“As a carbohydrate synthesis specialist, the Sussex mandate is to help researchers explore and exploit glycobiology. By making Pseudaminic Acid and its derivative available commercially, Sussex will help advance studies on bacteria that contain this modification,” said Dr. Brady Clark, President of Sussex Research. “Research with these products may eventually lead to alternative treatments for those suffering from infectious diseases where Pseudaminic Acid plays a role in their pathogenesis. We are delighted to make these important sugars available to researchers.”
About Sussex Research:
Sussex Research excels in the design, development and manufacture of novel molecules that incorporate glycotechnology. Sussex carbohydrate-based products and services enable researchers to explore and exploit glycobiology via facile introduction of carbohydrate recognition elements in biological molecules such as glycopeptides. The Sussex portfolio of advanced glycosylation products and carbohydrate building blocks enables assembly of oligosaccharides, glycoconjugates and carbohydrate-enhanced molecules. Sussex expertise and custom carbohydrate manufacturing capabilities advance external collaborations in drug discovery, therapeutic development and vaccine design. Sussex Research is the resource for glycosylation and carbohydrate synthesis. For more information, please visit www.sussex-research.com.
For Further Information Contact:
Sussex Research
Brady Clark, Ph.D.
Phone: 613-993-4402
Fax: 613-949-5993
bclark@sussex-research.com
www.sussex-research.com
